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EDITORIAL
Mulling over the odds of CETP inhibition
Arnold von Eckardstein*
Institute of Clinical Chemistry, University Hospital Zurich, Raemistrasse 100, CH 8091 Zurich, Switzerland
Online publish-ahead-of-print 22 January 2010
This editorial refers to ‘Safety and tolerability of dalcetra-
pib (RO4607381/JTT-705): results from a 48-week trial’†,
by E.A. Stein et al. on page 480
Both elevated plasma concentrations of LDL cholesterol and
low concentrations of HDL cholesterol are important risk
factors of coronary heart disease.1 In randomized controlled
trials of .100 000 individuals, lowering of LDL cholesterol with
statins was found to be safe and effective in reducing cardiovascular
morbidity and mortality by 20–40%.2 As the flip side of the coin,
60–80% of cardiovascular events are not prevented by statin
treatment. Therefore, and because low HDL cholesterol explains
some of the residual risk of patients with well controlled LDL
cholesterol levels, both lower treatment goals for LDL cholesterol
(,70 mg/dL/,1.7 mmol/L) and elevation of HDL cholesterol
above at least 40 mg/dL (.1.05 mmol/L) are propagated.3 The
clinical validity of this concept is currently evaluated in ongoing
randomized clinical endpoint trials of statin combination therapies
with ezitimibe, fenofibrate, nicotinic acid, or the cholesteryl ester
transfer protein (CETP) inhibitor dalcetrapib.
CETP exchanges cholesteryl esters of HDL with triglycerides
of apolipoprotein B (apoB)-containing lipoproteins (Figure 1).4
This has two important consequences in lipoprotein metabolism.
First, notably large HDL2 particles lose their cholesteryl esters
which have accumulated there as the result of efflux of
phospholipids and unesterified cholesterol from hepatocytes,
enterocytes, macrophages, and other cells, as well as subsequent
esterification by the enzyme lecithin:cholesterol acyltransferase
(LCAT). The HDL2 particles shrink in size and liberate lipid-free
apoA-I that undergoes either lipidation for regeneration of HDL
or glomerular filtration for renal elimination. Secondly, CETP
supports the transformation of the triglyceride-rich very low
density lipoproteins (VLDLs) into cholesteryl-ester rich LDLs
by enhancing the otherwise mainly lipolytic removal of
triglycerides and by inducing the accumulation of cholesteryl
esters (Figure 1).4 The physiological importance of CETP for
the regulation of VLDL/LDL and HDL metabolism originally
emerged from the observation of high HDL cholesterol and
low LDL cholesterol in Japanese subjects with homozygous
CETP deficiency.5
These observations as well as reports on reduced incidence of
chronic heart disease (CHD) and increased life expectancy of
CETP-deficient patients prompted several pharmaceutical
companies to develop CETP inhibitors for the prevention and
treatment of atherosclerosis. However, the first clinical evalu-
ation of this concept using the CETP inhibitor torcetrapib
recently failed to fulfil the hopes of patients, doctors, scientists,
and the pharmaceutical industry. Despite further reducing LDL
cholesterol by 15% and increasing HDL cholesterol by
.50%, the combination of atorvastatin with torcetrapib did not
prevent progression of carotid or coronary atherosclerosis
more effectively than atorvastatin alone,6,7 but produced an
excess of cardiovascular and overall mortality.8 However, it is
as yet unkown whether the failure of torcetrapib was caused
directly by CETP inhibition or indirectly by off-target effects
because torcetrapib also increased blood pressure, by stimulating
the synthesis of cortisol and aldosterone independently of CETP
inhibition.9 The researchers involved in the two imaging torcetra-
pib trials tried to address these questions by post hoc data ana-
lyses but they obtained discrepant results: the ILLUSTRATE
investigators found a significant regression of coronary atheroma
volume in the 25% subgroup of patients who experienced the
stongest increase in HDL cholesterol or reached the highest
HDL cholesterol levels.10 In contrast the RADIANCE investi-
gators found correlations of changes in carotid intima-media
thickness with changes of LDL cholesterol and blood pressure
but not HDL cholesterol.11
Thus it is still undecided whether CETP inhibition is a useful
target for anti-atherogenic therapy. In fact at least two other
CETP inhibitors, anacetrapib and dalcetrapib (formerly designated
as JTT705), which do not affect blood pressure and mineralocorti-
coid synthesis are undergoing clinical evaluation.9 Like the chemi-
cally related torcetrapib, anacetrapib fixes CETP to HDL,
irreversibly inhibits CETP by 90%, decreases LDL choleserol by
15%, and increases HDL cholesterol by 100% at the highest
dosage.12 In contrast, the chemically unrelated dalcetrapib is a
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much milder and reversible CETP inhibitor which interferes
with the formation of an important intramolecular disulfide
bridge.13
Stein and colleagues have reported the first mid-term follow-up
data on the safety and efficacy of dalcetrapib.14 They compared the
combination of atorvastatin with either 900 mg of dalcetrapib
(instead of the 600 mg phase III dose) or placebo in 135 individuals
for their effects on plasma CETP activity, lipids, and (apo)lipopro-
teins, as well as for adverse clinical effects during 24 and 48 weeks
of follow-up. In principal the authors confirmed the findings of pre-
vious short-term follow-up studies,13 namely an 50% decrease in
CETP activity, a 30% increase in HDL cholesterol, and a 15%
increase in apoA-I with little effect on LDL cholesterol. Impor-
tantly, dalcetrapib did not significantly increase the overall rate of
side effects.14
These findings are important for the continuation of the already
initiated phase III trials which are investigating the effects of the
statin–dalcetrapib combination on atherosclerotic plaque load in
coronary arteries, endothelial function, and hard clinical endpoints.
Until the disclosure of these studies, one can only speculate on the
benefits of dalcetrabip and CETP inhibition in general by exploring
previous data from observational genetic studies in humans and
animals as well as changes in biomarkers observed after treatment
with CETP inhibitors.
(i) Japanese carriers of CETP deficiency mutations had a low
CHD risk if they had HDL cholesterol levels .2 mmol/L
but had a normal or even an elevated risk if they had
normal HDL cholesterol levels ranging between 1 and
1.5 mmol/L15,16 or a combination of CETP deficiency and
low hepatic lipase activity.17 A recent meta-analysis of
46 studies with data on 27 196 coronary cases and 55 338
controls showed significant associations of three CETP
polymorphisms with a decrease in CETP activity and mass
by 8–10% and an increase in HDL cholesterol by 4–5%
with little reduced cardiovascular risk.18 However, under
certain conditions the same polymorphisms were found to
increase the cardiovascular risk, e.g. in women or hypertrigly-
ceridaemic subjects19,20 or in patients treated with statins.21 It
hence appears that low or high CETP activity influences
Figure 1 Role of cholesteryl ester transfer protein (CETP) in lipoprotein metabolism. Triglyceride-rich VLDLs are secreted by the liver and
further metabolized to LDLs by lipolysis of triglycerides (TGs), initially by lipoprotein lipase (LPL) and then by hepatic lipase (HL), and by CETP-
mediated enrichment with cholesteryl esters (CEs). HDL metabolism is a multistep process which involves the secretion of lipid-free apolipo-
proteins by the liver or intestine, the acquisition of phospholipids and cholesterol from cells via ATP binding cassette transporter A1 (ABCA1)
and ABCG1, the maturation by lecithin:cholesterol acyltransferase (LCAT)-mediated cholesterol esterification and phospholipid transfer
protein (PLTP)-mediated particle fusion, and the final delivery of lipids to the liver, mostly indirectly via CETP-mediated transfer to LDLs.
Thereby HDLs become transiently enriched in TGs which, however, are rapidly hydrolysed by HL so that ultimately small HDL particles
and lipid-free apoA-I are generated.
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cardiovascular risk depending on additional metabolic circum-
stances such as triglyceride levels and LDL receptor activity.
Although not consistent in all studies,22 the genetic data on
reduced statin efficacy in individuals carrying low CETP
activity alleles raise questions on the safety and utility of the
combination of statins with CETP inhibitors.
(ii) Animal models also provided controversial data on the role of
CETP in atherosclerosis.4 Wild-type mice lack CETP so that
only the effect of transgenic CETP overexpression on athero-
sclerosis could be investigated. In wild-type mice as well
as in hypercholesterolaemic mouse models, overexpression
of CETP increased atherosclerosis.23,24 In contrast, in
hypertriglyceridaemic mouse models and in mice overexpres-
sing LCAT, CETP overexpression reduced atherosclerosis
despite lowering HDL cholesterol.25,26 In rabbits, vaccination
against CETP as well as CETP inhibiton with either JTT705 or
antisense-nucleotides were found to increase HDL choles-
terol and reduce atherosclerosis.4
(iii) A few studies were undertaken to characterize the function-
ality of HDL after treatment of patients with either torcetra-
pib or dalcetrapib. Turnover studies revealed that the changes
in the size and concentration of HDL and LDL of patients
treated with torcetrapib result from delayed catabolism of
apoA-I and HDL and increased clearance of LDL.27
Whereas the clinical benefit of enhanced hepatic LDL
clearance has become evident in many clinical studies and
observations, the clinical benefit of delayed HDL catabolism
has not. On the one hand the increase in particle number
and size may improve the anti-atherogenic potential of
HDL, e.g. in stimulating cholesterol efflux from macrophages
via the ATP binding cassette transporter G128 and improving
endothelial function.29 On the other hand it is important to
bear in mind that CETP inhibition prolongs the half-life of
HDL which may make these particles more vulnerable
towards oxidative and enzymatic modifications and hence
turn them into dysfunctional and rather pro-atherogenic par-
ticles. In this regard, one observation of the efficacy study of
Stein and colleagues14 needs further attention: after 24 weeks
of treatment patients who received dalcetrapib had signifi-
cantly higher levels of C-reactive protein (CRP) in their
plasma than patients who received placebo. Although this
difference disappeared after 24 more weeks of treatment
and although the mean level of CRP did not pass the
current cardiovascular risk threshold of 2 mg/L this obser-
vation may indicate some dysfunctionality of HDL and
deserves further studies or post hoc analyses of frozen
plasma by the use of more sensitive CRP assays and tests
for other inflammatory markers.
Mulling over the odds of CETP inhibition for CHD prevention
can be even extended to HDL-modifiying therapies in general.
It is important to realize that the cholesterol in HDL is neither a
protective agent nor a reflection of the anti-atherogenic action
of HDL, e.g. in reverse cholesterol transport, but is rather an inte-
grated and indirect estimation of HDL particle size and number.30
At identical HDL cholesterol levels two individuals may differ con-
siderably in the number, size distribution, and composition of HDL
particles and hence atheroprotection. Since HDLs contain dozens
of bioactive proteins and lipids with potentially anti-atherogenic
activity there is a strong need for biomarkers that better reflect
the anti-atherogenicity of HDL than HDL cholesterol or apoA-I
concentrations. In addition, any novel HDL therapy must be sub-
jected to randomized clinical trials at an early stage to prove that
it does not only change the concentrations and composition of
HDL but also reduces progression or even induces regression of
atherosclerosis and lowers cardiovascular event rates. While scien-
tists and pharmaceutical companies pursuing CETP inhibition and
other HDL-modifiying therapies as a therapeutic target are to be
congratulated for continuing this risky endeavour, I’ll keep my
fingers crossed.
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